ChatGPT may respond to prompts with information that is false and/or outdated. Just as you would with any research, it is important to fact-check and use additional, authoritative sources of information before taking ChatGPT’s answer as definitive. Special care and attention should be paid when doing research whose results may have harmful impact on people, for example, Pharmacy and Health Sciences.
As of this writing, ChatGPT’s training corpus is largely built on texts produced before 2021. As a result, the information obtained may be incomplete and/or factually incorrect, especially in fields of study where new research is produced at a quick pace.
NOTE: The following example is meant to illustrate some of the problems in using ChatGPT for research in Pharmacy. It should not be taken as medical or pharmaceutical advice
In this example there is incorrect information:
Compare cibinqo to dupixent for the treatment of atopic dermatitis and provide full bibliographic references in the AMA Style.
Cibinqo and Dupixent are both FDA-approved medications for the treatment of atopic dermatitis, a chronic inflammatory skin condition. However, they have different mechanisms of action and clinical outcomes.
Cibinqo (bimagrumab) is a monoclonal antibody that targets and inhibits the activin type II receptor, which is involved in the regulation of muscle mass and inflammation. In a randomized, double-blind, placebo-controlled Phase 2b trial, Cibinqo demonstrated a significant reduction in the Eczema Area and Severity Index (EASI) score, a measure of disease severity, compared to placebo in patients with moderate to severe atopic dermatitis. However, the trial also reported a high incidence of injection site reactions and adverse events, including upper respiratory tract infections, headache, and diarrhea.
On the other hand, Dupixent (dupilumab) is a monoclonal antibody that blocks the interleukin-4 receptor alpha (IL-4Rα) and interleukin-13 (IL-13) pathways, which play a key role in the pathogenesis of atopic dermatitis. Dupixent has demonstrated significant efficacy in reducing the severity of atopic dermatitis symptoms in several randomized, double-blind, placebo-controlled Phase 3 trials. In these studies, Dupixent was shown to significantly reduce the EASI score, improve the overall disease severity, and improve quality of life compared to placebo, with a favorable safety profile.
Overall, while both medications show promise in the treatment of atopic dermatitis, Dupixent appears to be the more effective and safer option based on current clinical evidence.